Compare Pfizer Inc (PFE) vs TJX Companies Inc (TJX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs TJX Companies Inc — how do they compare? Pfizer Inc trades at $28.01 (market cap $158.56B), while TJX Companies Inc trades at $137.76 (market cap $152.62B). The key difference: Pfizer Inc and TJX Companies Inc are close in size by market cap, and Pfizer Inc pays the higher dividend (6.18%). Which is the better fit depends on your goals — on Pluang, investors hold Pfizer Inc for 158 Days and TJX Companies Inc for 97 Days on average.
| PFE | TJX | |
|---|---|---|
Market Cap | $158.56B | $152.62B |
Volume | 44,138,282 | 8,079,794 |
Sector | Health | Consumer Cyclical |
52-Week High | $29.02 | $168.41 |
52-Week Low | $23.67 | $122.84 |
Typical Hold Time | 158 Days | 97 Days |
Enterprise Value | $210.06B | $160.93B |
Dividend Yield | 6.18% | 1.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
TJX trades at $138.80, up 1.28% today, with a bullish technical trend and strong fundamentals. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 EPS expected at $1.33. Revenue grew to $56.36B in 2025, with a net income margin of 8.63%. Analysts are overwhelmingly bullish, with an 84.9% buy rating and a consensus price target of $174.15, implying 25% upside. Recent news highlights TJX's value proposition and merchandising strength in the off-price retail sector.
TJX presents a compelling investment opportunity driven by earnings growth, high profitability (ROE 62.17%), and positive analyst sentiment. Risks include competitive pressures, economic sensitivity, and valuation multiples above industry averages. The stock's momentum and fundamental strength support a favorable outlook, but investors should monitor execution against future earnings expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About TJX Companies Inc
TJX is a leading off-price retailer of apparel, home fashions, and other merchandise. It sells a variety of branded goods, opportunistically buying inventory from a network of over 21,000 vendors worldwide. TJX targets undercutting conventional retailers' regular prices by 20%-60%, capitalizing on a flexible merchandising network, relatively low-frills stores, and a treasure-hunt shopping experience to drive margins and inventory turnover. TJX derived 79% of fiscal 2022 revenue from the United States, with 11% from Europe (mostly the United Kingdom and Germany), 9% from Canada, and the remainder from Australia. The company operated 4,689 stores at the end of fiscal 2022 under the T.J. Maxx, T.K. Maxx, Marshalls, HomeGoods, Winners, Homesense, Winners, and Sierra banners.
Read more on TJX →
